Autor(es): Misra Namita; Bayry Jagadeesh; Ephrem Amal; Dasgupta Suryasarathi,Delignat Sandrine; Duong Van Huyen Jean-Paul; Prost Fabienne; Lacroix-Desmazes Sebastien; Nicoletti Antonino; Kazatchkine Michel D.; Kaveri Srini V.

Resumo: Intravenous immunoglobulin (IVIg) has been used in the treatment of primary and secondary antibody deficiencies for over 25 years. It is a safe preparation with no long-term side effects. IVIg was first demonstrated to be effective in autoimmune disorders, two decades ago, in the treatment of acute immune thrombocytopenia. Since then, the therapeutic efficacy of IVIg has been established in Guillain Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), myasthenia gravis (MG), dermatomyositis (DM), Kawasaki syndrome and the prevention of graft-versus-host disease in recipients of allogeneic bone marrow transplants and reported in a large number of other autoimmune and systemic inflammatory conditions.

Imprenta: Journal of Neurology, v. 252, supl 1-6, 2005

Identificador do objeto digital: 10.1007/s00415-005-1102-7

Descritores: Guillain-Barre Syndrome - Biosynthesis ; Guillain-Barre Syndrome - Cell ; Guillain-Barre Syndrome - Pathogenesis ; Guillain-Barre Syndrome - Proteins ; Guillain-Barre Syndrome - Antibodies ; Guillain-Barre Syndrome - Cytokines ; Guillain-Barre Syndrome - Immunology

Data de publicação: 2005

INDICADORES

ACESSO